Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
The Pharma Letter8h
Vigil moves into Phase II with Alzheimer's pill
Vigil Neuroscience advances VG-3927, a small molecule TREM2 agonist, into Phase II Alzheimer’s trials in Q3 2025 following ...